1 Title:

2 Ultrasound versus fluoroscopy as imaging guidance for percutaneous nephrolithotomy: A

- 3 systematic review and meta-analysis
- 4 Razman Arabzadeh Bahri^{1,2*}, Saba maleki³, Arman Shafiee⁴, Parnian Shobeiri¹
- ⁵ ¹ School of Medicine, Tehran University of Medical Science, Tehran, Iran
- ⁶ ² Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
- ³ School of Medicine, Guilan University of Medical Sciences (GUMS), Rasht, Guilan Province,
 Iran
- ⁹ ⁴ Student Research Committee, School of Medicine, Alborz University of Medical Sciences,
- 10 Karaj, Iran
- 11 Corresponding author*
- 12 Email: raz_bahri@yahoo.com

13 Abstract

Objectives: To determine whether the outcomes of ultrasound-guided percutaneous
 nephrolithotomy (UG-PCNL), an alternative to traditional fluoroscopy-guided percutaneous
 nephrolithotomy (FG-PCNL), are comparable.

Methods: A systematic search of PubMed, Embase, and the Cochrane Library was carried out to discover investigations comparing UG-PCNL to FG-PCNL, and accordingly, a meta-analysis of those studies was performed. The primary outcomes included the stone-free rate (SFR), overall complications based on Clavien-Dindo classification, duration of surgery, duration of patients' hospitalization, and hemoglobin (Hb) drop during the surgery. All statistical analyses and visualizations were implemented utilizing R software.

Results: Nineteen studies, including eight randomized clinical trials (RCTs) and eleven 23 24 observational cohorts, comprising 3016 patients (1521 UG-PCNL patients) and comparing UG-25 PCNL with FG-PCNL met the inclusion criteria of the current study. Considering SFR, overall complications, duration of surgery, duration of hospitalization, and Hb drop, our meta-analysis 26 27 revealed no statistically significant difference between UG-PCNL and FG-PCNL patients, with p-28 values of 0.29, 0.47, 0.98, 0.28, and 0.42, respectively. Significant differences were discovered between UG-PCNL and FG-PCNL patients in terms of the length of time they were exposed to 29 radiation (p-value< 0.0001). Moreover, FG-PCNL had shorter access time than UG-PCNL (p-30 value= 0.04). 31

32 **Conclusion:** UG-PCNL provides the advantage of requiring less radiation exposure while being

just as efficient as FG-PCNL; thus, this study suggests prioritizing the use of UG-PCNL.

Keywords: Fluoroscopy - Ultrasonography - Nephrolithotomy - Percutaneous - Urinary calculi Meta-analysis

3

4 Introduction

Urolithiasis is a common urological disease with increasing prevalence (1). Percutaneous 5 nephrolithotomy (PCNL) is a minimally invasive procedure for removing complex or large kidney 6 stones (2, 3) and is conventionally performed under fluoroscopic guidance. A major concern 7 8 related to fluoroscopy-guided percutaneous nephrolithotomy (FG-PCNL) is the effect of exposure 9 to ionizing radiation by patients, surgeons, and operating room personnel (4, 5). Thus, an alternative imaging technique for PCNL would be advantageous (6). To avoid radiation exposure, 10 some surgeons prefer ultrasound-guided percutaneous nephrolithotomy (UG-PCNL) (7). Given 11 the higher rate of availability of ultrasound (US) devices in most peripheral hospitals, the use of 12 13 UG-PCNL also increases the number of PCNL procedures. Also, the total cost of UG-PCNL is 30% less than that of FG-PCNL in every case (8). PCNL is performed in prone, supine, or flank 14 positions. The prone position is the preferred modality for creating percutaneous access and 15 localizing stones during FG-PCNL (9) although, in obese patients, it is not an ideal position(10). 16 UG-PCNL can also be performed in the flank or supine position with a lower risk of complications 17 during anesthesia(11). There have been various studies, including observational studies or clinical 18 trials, comparing the feasibility, safety, and efficacy of ultrasound-guided and fluoroscopy-guided 19 PCNL, but the conclusion has scarce available data and the choice between these modalities is 20 based on the preference of the urologist. Therefore, updating this data is mandatory. In addition, 21 there has not been a comprehensive assessment of randomized clinical trials (RCTs) and 22 23 observational cohort studies comparing UG-PCNL and FG-PCNL. Therefore, we aimed to systematically review and conduct a meta-analysis to compare the efficacy of UG-PCNL with FG-24 25 PCNL in different outcomes for the treatment of urolithiasis.

26 Methods and materials

This study was conducted based on Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. The protocol of this study is registered in PROSPERO
(CRD42022327222)

1

2 Search strategy

3 A comprehensive search was conducted in international databases, including Cochrane library, 4 PubMed, and Embase, for relevant studies published from the inception to March 19th, 2022. The search was conducted again for the determination of newly published and relevant studies one 5 6 week before the submission of the manuscript. The search keywords were categorized into three 7 groups: Ultrasound, fluoroscopy, and nephrolithotomy. In the ultrasound group, we used any possible keywords such as ultrasound, US, ultrasound-guided, ultrasonography, and 8 ultrasonographic. In the fluoroscopy group, we used all possible keywords, including fluoroscopy, 9 10 X-ray, and fluoroscopic. In the nephrolithotomy group, the keywords used in the search strategy 11 were percutaneous nephrolithotomy, minimally invasive percutaneous nephrolithotomy, and PCNL. The keywords were combined with "AND" between the groups, and with "OR" in each 12 group. 13

14

15 Eligibility criteria

The inclusion criteria for study selection were as follows: (a) patients with urolithiasis condition; (b) comparison of ultrasound-guided PCNL and fluoroscopy-guided PCNL; (c) reporting of at least SFR and complication rate, and (d) studies in the English language. The exclusion criteria for study selection were as follows: (a) non-randomized studies, (b) Meta-analysis studies, and (c) review studies. No limitation was imposed in this study for study sample sizes and patient characteristics.

22 Data extraction and quality assessment

The initial screening of studies was carried out by two reviewers independently based on titles and abstracts to exclude non-related studies. The full text of related studies was then reviewed for confirmation of eligibility criteria meeting and data extraction. The data extraction of each study using an Excel-based sheet were checked and discussed by two reviewers independently. The data sheet included the first author names, type of studies, year of publications, number of patients in ultrasound and fluoroscopy group, patients' characteristics, SFRs, PCNL techniques, multiple stone status, stone burden, hydronephrosis degree, ultrasound probe, sheath size, dilator,

complication rate, surgery time and Hb decrease after the surgery. The methodological quality of
the included studies was independently assessed by two reviewers using the national institute of
health (NIH) quality assessment tool for cohort studies and the risk of bias (RoB2) method of the
Cochrane Collaboration for RCTs.

5 **Outcomes**

Five primary outcomes and five secondary outcomes were evaluated and analyzed. The primary outcomes included the SFRs, overall complications based on Clavien-Dindo classification, duration of surgery, duration of patients' hospitalization, and hemoglobin (Hb) drop during the surgery. The secondary outcomes included need for blood transfusion, fever after the surgery, radiation exposure of the patients, time to access the stone, and the number of attempts by the surgeon for the procedure.

12 Statistical analysis

The risk ratio (RR) was used to summarize the pooled effect size of dichotomous outcomes, and 13 the standardized mean difference (SMD) was used for reporting the results of continuous 14 15 outcomes. Study heterogeneity was assessed using the Chi-square test and I2 statistic, with I2 values of <25% indicating a low amount of heterogeneity. A fixed effect meta-analysis was 16 performed in the case of low heterogeneity; otherwise, a random effect model was used. In order 17 to investigate any potential effects of the type of study, sub-group analysis was carried out based 18 19 on their design (whether a randomized controlled trial (RCT) or an observational cohort). Publication bias was assessed using funnel plots and Egger's regression test for funnel plot 20 21 asymmetry. We did not report publication bias for outcomes with less than ten studies included. A meta-regression was performed to investigate the possible association between the publication year 22 23 as a measure of clinicians' experience in performing US-guided PCNL and the effect size. Metaregression analyses were only done on primary outcomes. All statistical analyses and graphics 24 were carried out using R (version 4.1.3) (R Core Team, 2020) and the meta package. 25

26

27 **Results**

28 Study Characteristics

1 Nineteen studies, including eight RCTs and eleven observational cohorts comparing UG-PCNL

2 with FG-PCNL, were included in our study (Fig1). The characteristics of the included studies are

3 presented in Table1. The first study was published in 2008 and the majority of the studies have

- 4 been published in recent years (2016-2021). The sample size of the articles ranged from 45 to 906.
- 5 A total of 3016 patients were evaluated in the included studies (of which 1521 patients underwent
- 6 UG-PCNL)

7 Primary outcomes

8 SFR

Eighteen studies comprising 2815 patients (of which 1411 underwent UG-PCNL) were included 9 in our analysis (12-29). No significant differences were observed in the case of SFR between 10 ultrasound and fluoroscopy-guided patients (RR: 1.02; 95% CI: 0.98 to 1.06; p = 0.29; I2 = 46%) 11 (Fig. 2-A). Furthermore, no significant between-group differences were observed based on the 12 13 study design (p = 0.75). Our meta-regression analysis revealed no significant association between publication year (as a measure of clinicians' experience) and risk of SFR (p=0.81) (Fig. 5). Visual 14 inspection of the funnel plot revealed no possible source of small study effects (Fig. 3-A). This 15 was further confirmed by using the Eggers regression test for funnel plot asymmetry (p=0.40). 16

17 **Overall complication**

For comparing the rate of complications between groups, studies reporting the outcome of the 18 Clavien-Dindo classification system were included in this analysis. Sixteen studies reported 19 compared complications based on this classification (13-24, 26-29). These studies included 1346 20 21 and 1339 patients treated with ultrasound and fluoroscopy-guided PCNL, respectively. Metaanalysis of these studies revealed no significant difference in overall complication (RR: 0.88; 95% 22 CI: 0.62 to 1.25; p = 0.47; I2 = 62%) (Fig. 2-B). However, the results of our subgroup analysis 23 showed a significant reduction in the overall complication rate in the ultrasound-guided group 24 when pooling the results of RCTs independently (RR: 0.73; 95% CI: 0.59 to 0.90; I2 = 6%). No 25 significant association between publication year and complication was observed (p=0.80) (Fig. 26 5). Visual inspection of the funnel plot revealed no possible source of small study effects (Fig. 3-27 B). This was further confirmed by using the Eggers regression test for funnel plot asymmetry (p=28 0.62). 29

1 Duration of surgery

Sixteen studies, including 2521 patients (of which 1264 underwent ultrasound-guided PCNL), 2 were included in our analysis (12, 14-24, 26-29). No significant differences were observed in 3 operation time between ultrasound and fluoroscopy-guided patients (SMD: 0.00; 95% CI: -0.39 to 4 0.39; p = 0.98; I2 = 89%) (Fig. 2-C). No significant between-group differences were observed 5 based on the study design (p = 0.35). Our meta-regression revealed a reduced SMD by increasing 6 publication year (as a measure of clinicians' experience) (Fig. 5). Although this interpretation was 7 made based on a non-significant result (p=0.37). Visual inspection of the funnel plot revealed no 8 possible source of small study effects (Fig. 3-C). This was further confirmed by using the Eggers 9 10 regression test for funnel plot asymmetry (p=0.58).

11 Duration of hospitalization

Sixteen studies comprising 2345 patients (of which 1126 underwent ultrasound-guided PCNL) 12 13 were included in our analysis (12, 14-24, 27-29). No significant differences were observed in duration of hospitalization between ultrasound and fluoroscopy-guided patients (SMD: -0.09; 95% 14 CI: -0.27 to 0.08; p = 0.28; I2 = 81%) (Fig. 2-D). The pooled effect size from observational studies 15 showed a favorable outcome in ultrasound-guided patients (SMD: -0.17; 95% CI: -0.31 to -0.03; 16 I2 = 0%). Our meta-regression revealed a non-significant association between publication year and 17 duration of hospitalization (p=0.88) (Fig. 5). Visual inspection of the funnel plot revealed the 18 presence of small study effects as an indication of publication bias (Fig. 3-D). This was further 19 confirmed by using the Eggers regression test for funnel plot asymmetry (p=0.001). 20

21 Hb drop

Twelve studies comprising 2079 patients (of which 998 underwent ultrasound-guided PCNL) were included (12, 14, 16-18, 20-22, 24, 27-29). Overall, no significant differences were observed in Hb drop between ultrasound and fluoroscopy-guided patients after their operation (SMD: -0.07; 95% CI: -0.24 to 0.10; p = 0.42; I2 = 57%) (Fig. 2-E). The pooled results of RCTs showed a favorable outcome in ultrasound-guided patients (SMD: -0.12; 95% CI: -0.22 to -0.01; I2 = 0%). Our meta-regression revealed a non-significant association between publication year and duration of hospitalization (p= 0.41) (Fig. 5). Visual inspection of the funnel plot revealed no possible

source of small study effects (Fig. 3-E). This was further confirmed by using the Eggers regression
 test for funnel plot asymmetry (p= 0.65).

3 Secondary outcomes

4 Need for blood transfusion

Thirteen studies with 2238 patients (of which 998 underwent UG-PCNL) were included (12, 14, 15, 19-22, 24, 25, 27-30). Overall, no significant differences were observed in blood transfusion rate between ultrasound and fluoroscopy-guided patients (RR: 0.77; 95% CI: 0.44 to 1.36; p =0.37; I2 = 51%) (Fig. 4-A). The pooled results of RCTs showed a reduced need for blood transfusion in ultrasound-guided patients (RR: 0.42; 95% CI: 0.27 to 0.64; I2 = 10%). Visual inspection of the funnel plot revealed no possible source of small study effects (Fig. 3-F). This was further confirmed by using the Eggers regression test for funnel plot asymmetry (p= 0.55).

12 Fever

13 Twelve studies with 2103 patients (of which 1010 underwent UG- PCNL) were included (12, 14,

14 15, 18, 21-25, 27-29). No significant differences were observed between ultrasound and 15 fluoroscopy-guided patients (RR: 0.97; 95% CI: 0.67 to 1.40; p = 0.87; I2 = 39%) (Fig. 4-B). Our 16 subgroup analysis showed no significant differences between the results of RCTs and 17 observational studies (Between groups p= 0.36). Visual inspection of the funnel plot revealed no 18 possible source of small study effects (Fig. 3-G). This was further confirmed by using the Eggers 19 regression test for funnel plot asymmetry (p= 0.17).

20 **Radiation exposure**

21 Seven studies comprising 811 patients (of which 386 underwent UG- PCNL) were included (13,

22 15-17, 20, 28, 30). When comparing the duration for which patients were exposed to radiation,

23 significant differences between ultrasound-guided patients and fluoroscopy-guided patients were

24 found. (SMD: -1.54; 95% CI: -2.29 to -0.79; p < 0.0001; I2 = 94%) (Fig. 4-C).

25 Access time

Six studies, including 664 patients (of which 330 underwent UG-PCNL), were included (12, 18, 19, 24, 29, 30). Our analysis revealed a shorter time needed for having access through the fluoroscopy-guided technique. (SMD: 0.85; 95% CI: 0.04 to 1.66; p= 0.04; I2 = 95%) (Fig. 4-D).

1 Number of attempts

- 2 Three studies, including 368 patients (of which 184 underwent UG-PCNL), were included (13, 16,
- 3 27). No significant differences were observed between ultrasound and fluoroscopy-guided patients
- 4 (SMD: -0.51; 95% CI: -2.18 to 1.16; p=0.54; I2 = 98%) (Fig. 4-E).

5 **Discussion**

6 To remove the renal stones, PCNL is offered with the highest SFR alongside high 7 complication(31). SFR is defined as the absence of residual stones, or the presence of residual 8 stone fragments less than 4 mm in size in follow-up studies such as kidney ultrasound and non-9 contrast computed tomography (CT) (32).

The indications for PCNL are stones larger than 20 mm, staghorn, and partial staghorn calculi(33).
 The contraindications for PCNL include pregnancy, bleeding disorders, and uncontrolled urinary
 tract infections(34).

13 PCNL is an efficient technique for removing large and complex stones with high success and low morbidity rates(35). PCNL is performed by making a small incision in the flank area under 14 15 fluoroscopy or ultrasound guidance(36). PCNL under ultrasound guidance has some advantages, including the absence of ionizing radiation, shorter time of the procedure, less puncture, and no 16 more use of contrast agents(37-39). To decrease complications like blood loss, postoperative pain, 17 and renal damage due to larger instruments, a modification of the standard procedure was 18 propounded (41). In fluoroscopy-guided PCNL, contrast is injected through a urethral catheter. 19 Puncture failure and re-do FG-PCNL can be mentioned as a disadvantage of this procedure(40, 20 21 41). Some studies mention that UG-PCNL in the flank or the prone position has a higher success rate and fewer complications compared with FG-PCNL(7, 42). In addition, mini-PCNL is a 22 standard technique in the treatment of renal and upper ureteric stones using a 28-30 F 23 ureteroscope(43). 24

In 2018, Yu-Hsiang and his colleagues published a meta-analysis comparing UG-PCNL with FGPCNL(44). It had eight included articles, and based on their analysis, they reported that UG-PCNL
had a significantly lower complication rate and also fewer intraoperative complications than FGPCNL(45, 46). Accordingly, UG-PCNL was also associated with reduced inadvertent organ injury
risks. Therefore, it can be concluded that ultrasound provides information about the surrounding

viscera, determines the depth of needle penetration, and identifies the area posterior to the anterior 1 2 calves when comparing the different complication rates(47). Due to its analysis, UG-PCNL in the 3 supine position had a higher SFR and significantly lower complication rate than FG-PCNL in the supine position. According to its results, it did not imply statistically significant differences in 4 SFR. however, it mentioned if a patient is an appropriate case for a supine position PCNL, like 5 patients with cardiovascular disease or spinal deformities, UG-PCNL can be a better choice than 6 FG-PCNL(11, 48). In mini-PNCL, they perform with a smaller percutaneous tract by using a 7 miniature endoscope. Accordingly, mini-PCNL was associated with less bleeding and 8 postoperative pain during the procedure(49, 50). 9

10 We conducted a systematic review and meta-analysis of efficacy and safety in UG-PCNL versus FG-PCNL with 19 articles included. This study was the first meta-analysis to evaluate ultrasound 11 12 versus fluoroscopy as imaging guidance for percutaneous nephrolithotomy, including RCTs and observational Cohort studies. The sample size of the articles ranged from 45 to 906. A total of 13 14 3016 patients were evaluated in the included studies (of which 1521 patients underwent UG-PCNL). A regression analysis was done based on publication year and approaching recent years, 15 16 with increasing experience in performing UG-PCNL. A better result was seen than FG-PCNL. Outcomes were considered in this meta-analysis in two groups. Each group had five sub-groups. 17 18 Primary outcomes included SFR, overall complications, duration of surgery, duration of hospitalization, and Hb drop. Secondary outcomes considered the need for blood transfusion, 19 fever, radiation exposure, access time, and the number of attempts. In most outcomes except 20 radiation exposure and access time, no significant differences were observed between ultrasound 21 22 and fluoroscopy-guided studies. Based on our analysis, RCT studies presented fewer complication rates compared to Cohort studies. In summary, comparing the results of this study to the systematic 23 review and meta-analysis published in 2018, most outcomes did not display significant differences. 24 25 Generally, between these two methods considered in this study, the results were in favor of UG-PCNL. 26

27 Limitations

There are multiple reasons for the heterogeneity of the included studies and also the conflicting results. On the one hand, the patients had different baseline characteristics, including body mass index and hydronephrosis degree. On the other hand, the procedure was conducted in various

positions. In addition, ultrasound is operator-dependent, and its practicality is based on machine
 properties and operator expertise.

3 Conclusion

According to the less radiation exposure when using the UG-PCNL technique, we suggest prioritizing the utilization of UG-PCNL in treating renal stones. Regarding the fact that the experience and level of expertise of the ultrasound performer may affect the findings, it is recommended to prepare a program to train people who perform the procedure. This could reduce the errors, which are mainly due to the lack of organized training programs and sufficient skills.

9 Acknowledgments

10 We thank all the authors of the included studies and all those who contributed to the present study.

11 Author Contributions

- 12 Conceptualization: Razman Arabzadeh Bahri.
- 13 Data curation: Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee.
- 14 Formal analysis: Arman Shafiee.
- 15 Investigation: Razman Arabzadeh Bahri, Saba Maleki.
- 16 **Methodology:** Arman Shafiee.
- 17 Supervision: Parnian Shobeiri.
- 18 Visualization: Razman Arabzadeh Bahri.
- 19 Writing original draft: Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee.
- 20 Writing review & editing: Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee, Parnian
- 21 Shobeiri.
- 22

23			
24			
25			
26			
27			
28			
29			

2	1. Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investigative and clinical
3	urology. 2017;58(5):299-306.
4 5	2. Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU guidelines on interventional treatment for urolithiasis. European urology. 2016;69(3):475-82.
6	3. Assimos D. Krambeck A. Miller NL. Monga M. Murad MH. Nelson CP. et al. Surgical management
7	of stones: American urological association/endourological society guideline. PART I. The Journal of
8	urology. 2016;196(4):1153-60.
9	4. Hidajat N, Wust P, Kreuschner M, Felix R, Schroder R. Radiation risks for the radiologist
10	performing transjugular intrahepatic portosystemic shunt (TIPS). The British Journal of Radiology.
11	2006;79(942):483-6.
12	5. Vano E, Kleiman NJ, Duran A, Romano-Miller M, Rehani MM. Radiation-associated lens opacities
13	in catheterization personnel: results of a survey and direct assessments. Journal of Vascular and
14	Interventional Radiology. 2013;24(2):197-204.
15	6. Mancini JG, Raymundo EM, Lipkin M, Zilberman D, Yong D, Bañez LL, et al. Factors affecting
16	patient radiation exposure during percutaneous nephrolithotomy. The Journal of urology.
17	2010;184(6):2373-7.
18	7. Hosseini MM, Hassanpour A, Farzan R, Yousefi A, Afrasiabi MA. Ultrasonography-guided
19	percutaneous nephrolithotomy. Journal of endourology. 2009;23(4):603-7.
20	8. Hudnall M, Usawachintachit M, Metzler I, Tzou DT, Harrison B, Lobo E, et al. Ultrasound
21	guidance reduces percutaneous nephrolithotomy cost compared to fluoroscopy. Urology. 2017;103:52-
22	8.
23	9. Ahmad AA, Alhunaidi O, Aziz M, Omar M, Al-Kandari AM, El-Nahas A, et al. Current trends in
24	percutaneous nephrolithotomy: an internet-based survey. Therapeutic Advances in Urology. 2017;9(9-
25	10):219-26.
26	10. Kwee MM, Ho Y-H, Rozen WM. The prone position during surgery and its complications: a
27	systematic review and evidence-based guidelines. International surgery. 2015;100(2):292-303.
28	11. Karaolides T, Moraitis K, Bach C, Masood J, Buchholz N. Positions for percutaneous
29	nephrolithotomy: Thirty-five years of evolution. Arab Journal of Urology. 2012;10(3):307-16.
30	12. Karami H, Rezaei A, Mohammadhosseini M, Javanmard B, Mazloomfard M, Lotfi B.
31	Ultrasonography-guided percutaneous nephrolithotomy in the flank position versus fluoroscopy-guided
32	percutaneous nephrolithotomy in the prone position: a comparative study. J Endourol. 2010;24(8):1357-
33	61.
34	13. Agarwal M, Agrawal MS, Jaiswal A, Kumar D, Yadav H, Lavania P. Safety and efficacy of
35	ultrasonography as an adjunct to fluoroscopy for renal access in percutaneous nephrolithotomy (PCNL).
36	BJU Int. 2011;108(8):1346-9.
37	14. Andonian S, Scoffone CM, Louie MK, Gross AJ, Grabe M, Daels FP, et al. Does imaging modality
38	used for percutaneous renal access make a difference? A matched case analysis. J Endourol.
39	
40	15. Basiri A, Mirjaili MA, Kardoust Parizi M, Moosa Nejad NA. Supplementary X-ray for ultrasound-
41 42	guided percutaneous nephrolitholomy in supine position versus standard technique: a randomized
4Z 12	Controlled trial. 0101 mt. 2013;90(4):399-404.
45 //	renal access for a trainee urologist: ultrasonography or fluoroscopy? Posults of a prospective
 15	randomized trial Endourol 2014.28(12).1/6/-9
46	17 Chi T. Masic S. Li L. Usawachintachit M. Ultrasound Guidance for Renal Tract Access and Dilation
47	Reduces Radiation Exposure during Percutaneous Nephrolithotomy, Adv Urol, 2016-2016-3840697
••	

1 18. Falahatkar S, Allahkhah A, Kazemzadeh M, Enshaei A, Shakiba M, Moghaddas F. Complete 2 supine PCNL: ultrasound vs. fluoroscopic guided: a randomized clinical trial. Int Braz J Urol. 3 2016:42(4):710-6. 4 19. HamdyAboutaleb M, Mohammed El-Shazly MJAS. Ultrasound versus fluoroscopy guided 5 percutaneous nephrolithotomy for treatment of calculi in hydronephrotic kidneys. 2016;2:015. 6 Usawachintachit M, Masic S, Chang HC, Allen IE, Chi T. Ultrasound Guidance to Assist 20. 7 Percutaneous Nephrolithotomy Reduces Radiation Exposure in Obese Patients. Urology. 2016;98:32-8. 8 Ng FC, Yam WL, Lim TYB, Teo JK, Ng KK, Lim SK. Ultrasound-guided percutaneous 21. 9 nephrolithotomy: Advantages and limitations. Investig Clin Urol. 2017;58(5):346-52. 10 22. Sun H, Zhang Z, Huang G, Wan SP, Chen H, He B, et al. Fluoroscopy versus ultrasonography 11 guided mini-percutaneous nephrolithotomy in patients with autosomal dominant polycystic kidney 12 disease. Urolithiasis. 2017;45(3):297-303. 13 23. Sun W, Liu MN, Yang ZW, Wang Q, Xu Y. Ultrasound-guided percutaneous nephrolithotomy for 14 the treatment in patients with kidney stones. Medicine (Baltimore). 2017;96(51):e9232. 15 24. Zhu W, Li J, Yuan J, Liu Y, Wan SP, Liu G, et al. A prospective and randomised trial comparing 16 fluoroscopic, total ultrasonographic, and combined guidance for renal access in mini-percutaneous 17 nephrolithotomy. BJU Int. 2017;119(4):612-8. 18 25. Abed SM, Alhamdani NJIJMS, 18. Ultrasonographic guidance versus fluoroscopic guidance for 19 renal access in percutaneous nephrolithotomy (PCNL): a comparative study. 2019;335. 20 26. Armas-Phan M, Tzou DT, Bayne DB, Wiener SV, Stoller ML, Chi T. Ultrasound guidance can be 21 used safely for renal tract dilatation during percutaneous nephrolithotomy. BJU Int. 2020;125(2):284-91. 22 Birowo P, Raharja PAR, Putra HWK, Rustandi R, Atmoko W, Rasyid N. X-ray-free ultrasound-27. 23 guided versus fluoroscopy-guided percutaneous nephrolithotomy: a comparative study with historical 24 control. Int Urol Nephrol. 2020;52(12):2253-9. 25 28. Sahan A, Cubuk A, Ozkaptan O, Ertas K, Canakci C, Eryildirim B, et al. Safety of Upper Pole 26 Puncture in Percutaneous Nephrolithotomy with the Guidance of Ultrasonography versus Fluoroscopy: 27 A Comparative Study. Urol Int. 2020;104(9-10):769-74. 28 29. Eslahi A, Ahmed F, Hosseini MM, Rezaeimehr MR, Fathi N, Nikbakht HA, et al. Minimal invasive 29 percutaneous nephrolithotomy (Mini-PCNL) in children: Ultrasound versus fluoroscopic guidance. Arch 30 Ital Urol Androl. 2021;93(2):173-7. 31 30. Basiri A, Ziaee AM, Kianian HR, Mehrabi S, Karami H, Moghaddam SM. Ultrasonographic versus 32 fluoroscopic access for percutaneous nephrolithotomy: a randomized clinical trial. J Endourol. 33 2008;22(2):281-4. 34 31. Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, et al. Surgical management 35 of stones: American urological association/endourological society guideline, PART I. 2016;196(4):1153-36 60. 37 32. Atis G, Culpan M, Pelit ES, Canakci C, Ulus I, Gunaydin B, et al. Comparison of Percutaneous 38 Nephrolithotomy and Retrograde Intrarenal Surgery in Treating 20-40 mm Renal Stones. Urol J. 39 2017;14(2):2995-9. Desai M, Sun Y, Buchholz N, Fuller A, Matsuda T, Matlaga B, et al. Treatment selection for 40 33. 41 urolithiasis: percutaneous nephrolithomy, ureteroscopy, shock wave lithotripsy, and active monitoring. 42 World journal of urology. 2017;35(9):1395-9. 43 34. Preminger GM, Assimos DG, Lingeman JE, Nakada SY, Pearle MS, Wolf JS. Chapter 1: AUA 44 guideline on management of staghorn calculi: diagnosis and treatment recommendations. The Journal 45 of urology. 2005;173(6):1991-2000. 46 35. Sun W, Liu M-n, Yang Z-w, Wang Q, Xu Y. Ultrasound-guided percutaneous nephrolithotomy for 47 the treatment in patients with kidney stones. Medicine. 2017;96(51).

1 36. Fernström I, Johansson B. Percutaneous pyelolithotomy: a new extraction technique. 2 Scandinavian journal of urology and nephrology. 1976;10(3):257-9. 3 Zegel H, Pollack H, Banner M, Goldberg B, Arger P, Mulhern C, et al. Percutaneous nephrostomy: 37. 4 comparison of sonographic and fluoroscopic guidance. American Journal of Roentgenology. 5 1981;137(5):925-7. 6 38. Basiri A, Ziaee SAM, Nasseh H, Kamranmanesh M, Masoudy P, Heidary F, et al. Totally 7 ultrasonography-guided percutaneous nephrolithotomy in the flank position. Journal of endourology. 8 2008;22(7):1453-8. 9 39. Gupta S, Gulati M, Suri S. Ultrasound-guided percutaneous nephrostomy in non-dilated 10 pelvicaliceal system. Journal of clinical ultrasound. 1998;26(3):177-9. 11 40. HamdyAboutaleb M, Mohammed El-Shazly M. Ultrasound versus fluoroscopy guided 12 percutaneous nephrolithotomy for treatment of calculi in hydronephrotic kidneys. Ann SurgInt. 13 2016:2:015. 14 41. Inanloo SH, Yahyazadeh SR, Rashidi S, Amini E, Nowroozi MR, Ayayti M, et al. Feasibility and safety of ultrasonography guidance and flank position during percutaneous nephrolithotomy. 15 16 2018;200(1):195-201. 17 42. Basiri A, Ziaee AM, Kianian HR, Mehrabi S, Karami H, Moghaddam SMH. Ultrasonographic versus 18 fluoroscopic access for percutaneous nephrolithotomy: a randomized clinical trial. Journal of 19 endourology. 2008;22(2):281-4. 20 43. Desai J, Zeng G, Zhao Z, Zhong W, Chen W, Wu W. A novel technique of ultra-mini-percutaneous 21 nephrolithotomy: introduction and an initial experience for treatment of upper urinary calculi less than 22 2 cm. BioMed research international. 2013;2013. 23 44. Yang Y-H, Wen Y-C, Chen K-C, Chen C. Ultrasound-guided versus fluoroscopy-guided 24 percutaneous nephrolithotomy: a systematic review and meta-analysis. World journal of urology. 25 2019;37(5):777-88. 26 Ng FC, Yam WL, Lim TYB, Teo JK, Ng KK, Lim SK. Ultrasound-guided percutaneous 45. 27 nephrolithotomy: advantages and limitations. Investigative and clinical urology. 2017;58(5):346-52. 28 Wang K, Zhang P, Xu X, Fan M. Ultrasonographic versus fluoroscopic access for percutaneous 46. 29 nephrolithotomy: a meta-analysis. Urologia internationalis. 2015;95(1):15-25. 30 47. Lojanapiwat B. The ideal puncture approach for PCNL: Fluoroscopy, ultrasound or endoscopy? 31 Indian journal of urology: IJU: journal of the Urological Society of India. 2013;29(3):208. 32 Manohar T, Jain P, Desai M. Supine percutaneous nephrolithotomy: effective approach to high-48. 33 risk and morbidly obese patients. Journal of endourology. 2007;21(1):44-9. 34 49. Jackman SV, Docimo SG, Cadeddu JA, Bishoff JT, Kavoussi LR, Jarrett TW. The "mini-perc" 35 technique: a less invasive alternative to percutaneous nephrolithotomy. World journal of urology. 36 1998;16(6):371-4. 37 50. Haghighi R, Zeraati H, Zade MG. Ultra-mini-percutaneous nephrolithotomy (PCNL) versus 38 standard PCNL: A randomised clinical trial. Arab Journal of Urology. 2017;15(4):294-8. 39



Fig. 1: PRISMA flowchart of the literature search and selection of the articles.

				0	A) Stone-free	rate			
	Study	Experim Events	ental Total Ev	Control vents Total	Risk Ratio	RR	95%-CI (c	Weight ommon) (Weight random)
	RCT Zhu 2016 Karami 2009 Agrawal 2010 Jagtap 2014 Andonian 2013 Sun 2017 Felahatkar 2016 Basiri 2013 Common effect mode Random effects mode Hoterogenesky. 2° = 40%	94 26 112 32 361 34 20 34	147 30 112 32 453 43 26 43 000	108 145 27 30 112 112 32 32 333 453 31 43 31 7 25 30 48 806		0.86 (0 0.96 (0 1.00 (0 1.08 (1 1.10 (1 1.13 (0 1.21 (0 1.03 (0 1.01 (0	74, 1.00] .80, 1.16] .98, 1.06] .94, 1.06] .01, 1.17] .86, 1.40] .80, 1.59] .93, 1.57] .99, 1.08] .97, 1.06]	10.4% 2.6% 10.8% 3.1% 3.0% 1.7% 2.8% 66.3%	4.6% 3.4% 21.3% 14.0% 12.1% 2.1% 1.8% 1.8%
	Cohort Abed 2019 Usawachintachit 2016 HamdyAboutaleb 2010 Sun 2016 Sahan 2020 Eslahi 2021 Armas-Phan 2019 Chi 2016 Birowo 2020 Ng 2017 Common effect mode Random effects mode	22 28 38 13 54 34 72 38 34 48	35 39 42 14 72 35 138 38 40 72 525	28 35 35 42 46 49 23 24 81 105 33 35 19 38 34 38 29 40 49 112 518		0.79 [0 0.86 [0 0.96 [0 0.97 [0 1.03 [0 1.12 [1 1.17 [0 1.152 [1 1.05 [1 1.03 [0	58; 1.06] 68; 1.09] 85; 1.09] 82; 1.15] 82; 1.15] 93; 1.14] 93; 1.49] 93; 1.49] 93; 1.48] 93; 1.48] 93; 1.48] 93; 1.48] 93; 1.12] 98; 1.12]	2.7% 3.2% 4.1% 6.3% 3.2% 3.3% 2.9% 3.3% 2.8% 3.3% 3.3%	1.4% 2.2% 6.6% 4.0% 4.0% 8.6% 1.0% 7.8% 2.3% 1.8%
v preprint doi: https://doi.org/10 ich was not certified by peer i	1101/2022 10113 222810 eview) is the author/funde It is made available und	46; this vers ∋r, who has er a CC-B¥	ion poste granted n 4.0 Interr	d October 13, nedRxiv a lice lational license	2022. The copyright hole nse to display the preprir	der for this preprint 1 nt in perpetuity.02	.00; 1.08] .98; 1.06]	100.0%	100.0%
				(B) (Overall compl	ications			
	Study	Experime Events	ental Fotal Ev	Control ents Total	Risk Ratio	RR	95%-CI (c	Weight ommon) (Weight random)
	RCT Basiri 2013 Felahatkar 2016 Zhu 2016 Sun 2017 Jagtap 2014 Andonian 2013 Agrawal 2010 Common effect model Random effects mode Heterogenety: $J^2 = 6\%$	t^{2} t^{7} 5 84 2 $\tau^{2} = 0.0402$	43 26 147 43 32 453 112 856 <i>p</i> = 0.38	7 46 6 25 31 145 9 43 6 32 98 453 2 112 856		0.15 [0 0.32 [0 0.54 [0 0.83 [0 0.83 [0 0.88 [0 1.00 [0 0.73 [0 0.68 [0	02; 1.19] 07; 1.44] 31; 0.939 20; 1.52] 28; 2.46] 66; 1.11] 14; 6.969 59; 0.90] 49; 0.94]	2 5% 2 3% 11.5% 3 3% 2 2% 36.1% 0.7% 58.5%	2.3% 3.7% 9.0% 5.9% 5.5% 10.8% 2.5%
	Cohort Eslahl 2021 Chi 2016 Sahan 2020 HamdyAboutaleb 2016 Ng 2017 Armas-Phan 2019 Birewe 2020 Sun 2016 Usawashintachit 2016 Common effect model Random effects mode	5 1 4 32 25 18 10 10	35 38 72 42 72 138 40 14 39 490	21 35 2 38 33 105 4 49 40 112 5 30 12 40 7 24 3 42 483		0.24 [0 0.50 [0 0.717 [0 1.24 [0 1.30 [0 2.45 [1 3.59 [1. 1.06 [0 1.13 [0	10; 0.58] 05; 5.28] 42; 1.18] 31; 4.38] 87; 1.78] 57; 3.35] 84; 2.69] 21; 4.96] 07; 12.09] 86; 1.32] 68; 1.89]	7,7% 0,7% 9,9% 1,4% 11,5% 2,9% 4,4% 1,9% 1,1% 41,5%	6.8% 1.9% 9.2% 4.4% 10.2% 6.6% 8.7% 7.8% 4.8%
	Heterogeneity: $I' = 69\%$ Common effect model Random effects model Heterogeneity: $I^2 = 62\%$ Test for subgroup differ Test for subgroup differ	$\tau^2 = 0.402$ $\tau^2 = 0.278$ ences (com ences (rand	4, p < 0.0 1346 8, p < 0.0 mon effection effect	1339 (1): $\chi_{1}^{2} = 6.94$, (s): $\chi_{1}^{2} = 2.73$,	df = 1 (p = 0.01) df = 1 (p = 0.10)	0.87 [0 0.88 [0	.75; 1.01] 62; 1.25]	100.0%	100.0%
				(C)	Duration of s	urgery			
	Study Te	Expe otal Mean	erimental SD	Total Mean	Control Standard SD Diffe	fised Mean brence SM	D 95%-C	Weight I (common)	Weight (random)
	RCT Sun 2017 Andonian 2013 Zhu 2016 Basiri 2013 Jagtap 2014 Felahatkar 2016 Karami 2009 Common effects model Hoterogenety. r ² = 83%. r ²	43 108.40 453 79.30 147 60.60 43 136.80 32 50.30 26 88.46 30 44.70 774 = 0.3058, p <	31 7000 48 8000 32 9000 138 0000 17 1000 39 4900 6 4000	43 113 20 453 84.60 145 63.60 46 137.10 32 49.20 25 79.58 30 34.90 774	34.5000 42.0000 32.5000 138.0000 16.8000 32.6000 5.1000		4 [-0.57; 0.28 2 [-0.25; 0.01 9 [-0.32; 0.01 6 [-0.42; 0.41 6 [-0.43; 0.55 4 [-0.31; 0.79 7 [1.06; 2.26 4 [-0.14; 0.06 0 [-0.24; 0.64	3.6% 38.1% 12.3% 2.7% 2.7% 1.2.1% 1.8% 64.4%	6 3% 6 7% 6 5% 6 3% 6 7% 5 9% 44 0%
	Cohort HamdyAboutaleb 2016	42 105.00	7.9000	49 130.00	11.6000	-24	16 [-3.01; -1.91]	1 2.1%	6.0%





Fig. 2: Forest plots of primary outcomes of UG-PCNL (experimental) versus FG-PCNL (control)





Fig. 3 Funnel plots of outcomes reported in at least 10 studies







Fig. 4 Forest plots of secondary outcomes of UG-PCNL (experimental) versus FG-PCNL (control)





Fig. 5 Results of meta-regression. Effects of publication year and the experience of the clinician on primary outcomes

Table 1.	Characteristics	of Included	Studies
----------	-----------------	-------------	---------

First Author	Type of Study	Cases (UG/FG)	Mean Age (UG/FG)	Sex Male n(UG/FG)	Mean BMI (UG/FG)	SFR (%)	PCNL Technique	Multiple Stones	Stone Location (UG/FG)	Stone Burden	Hydronephrosis Degree	Ultrasound Probe	Sheath Size	Dilator
Basiri et al., 2008	RCT	50/50	40.7/41.6	34/31	25/24.6	N/A	Flank: 100/100	0/0	Inferior: 40/40 Middle: 7/9 Superior: 3/1	24/27	Mild: 28/32 - Moderate: 40/42 - Severe: 32/26	3.5 MHz	30 F	Ampiatz
Karami et al., 2010	RCT	30/30	40.9/39.4	18/19	27.8/26	86.6/90	Flank/Prone	0/0	Superior calyx: 3/2 Middle calyx: 7/7 Inferior calix: 14/17 Renal pelvis: 6/4	28.7/27.4	Mild: 40/46 - Moderate: 53/36 - Severe: 6/16	3.5 MHz	28-30 F	Amplatz
Agarwal et al., 2011	RCT	112/112	31/35	N/A	N/A	100/100	Prone: 100/100	N/A	N/A	280/230mm2	N/A	3.5 MHz	26-28 F	Amplatz
Andonian et al., 2013	Cohort	453/453	50.2/47.9	62.5%/37. 5%	N/A	79.8/73.5	Prone: 93.8/84.1 - Supine: 6.2/15.9	56.3/67.5	Upper calyx: 8.9/8.8 Middle calyx: 39.2/11.1 Lower calyx: 44.8/68.1 Multiple calyces: 7.1/11.9	349/456.6	N/A	N/A	22.6/29.5	Baloon: 9.9/58.7 - Telescopic: 90.2/41.2
Basiri et al., 2013	RCT	43/46	45.7/44.8	30/31	25.29/24.8 6	73.9/65.2	Supine/Prone	30/43	Renal pelvis: 16/15 Inferior calyo: 10/8 Middle calyo: 4/3 Renal pelvis + inferior calyo: 7/10 Renal pelvis + middle calyo: 1/8 Middle and inferior calices: 5/2	N/A	N/A	3.5 MHz	28-30 F	Amplatz
Jagtap et al., 2014	RCT	32/32	40.7/44.5	25/20	N/A	100/100	Prone: 100/100	9//6	Superior calyx: 3/2 Middle calyx: 3/7 Inferior calyx: 10/10 Renal pelvis: 13/11	21/22	Mild: 40/46 - Moderate: 34/31 - Severe: 6/6	3.5 MHz	28 F	Amplatz
Falahatkar et al., 2016	RCT	26/25	48.41/51.1 7	17/15	28.14/26.3 1	76.9/68	Supine: 100/100	N/A	N/A	26.48/30.44	N/A	N/A	N/A	Amplatz
Chi et al., 2016	Cohort	38/38	52.7/52.9	17/19	26.1/30.3	100/89.4	Prone: 100/100	18.4/5.3	Calyceal: 12(31.6)/9(23.7) Renal pelvic: 10(26.3)/14(36.8) Proximal urethral: 3(7.9)/7(18.4)	N/A	Mild: 21.1/24.2 - Moderate: 21.1/21.1 - Severe: 5.2/5.2	N/A	24-30 F	Balloon
Sun et al., 2016	Retrospective Cohort	20/25	49.2/47.3	14/17	24.5/22.8	92.8/95.8	Prone: 100/100	60/56	Pelvis or proximal urether: 4/5	N/A	None or mild: 40/60 - Moderate or Severe: 60/40	N/A	18 F	N/A
Hamdy et al., 2916	Retrospective Cohort	42/49	40.2/43	35/39	N/A	80/83.7	Prone: 100/100	N/A	N/A	N/A	Mild: 33.3/77.5 - Moderate: 23.8/18.3 - Severe: 42.8/4	3.5-5 MHz	30 F	Amplatz
Usawa et al., 2016	Cohort	93/42	\$1.7/\$4.4	38/15	28.7/30.4	77.4/83.4	Prone: 100/100	16.1/7.1	Calyceal: 22(23.7)/12(28.6) Pelvic: 23(24.7)/11(26.2)	N/A	Mild: 34.4/28.6 - Moderate: 16.1/21.4 - Severe: 6.5/4.8	3.5 MHz	N/A	N/A
Ng et al., 2017	Cohort	72/112	55.6/52.6	50/87	N/A	66.7/43.7	Prone: 100/100	N/A	N/A	N/A	Mild: 44.4/37.5 - Moderate: 18.1/23.2 - Severe: 15.3/16.1	N/A	30 F	Ampiatz
Sun et al., 2017	RCT	43/43	42.9/45.1	29/32	24.2/24.5	79.1/69.8	Supine: 100/100	N/A	Renal pelvis: 15/17 Inferior calyx: 11/10 Middle calyx: 5/4 Renal pelvis + inferior calyx: 7/6	29.4/30.1	N/A	3.5 MHz	30 F	Amplatz

First Author	Type of Study	Cases (UG/FG)	Mean Age (UG/FG)	Sex Male n(UG/FG)	Mean BMI (UG/FG)	SFR (%)	PCNL Technique	Multiple Stones	Stone Location (UG/FG)	Stone Burden	Hydronephrosis Degree	Ultrasound Probe	Sheath Size	Dilator
									Renal pelvis + middle calyx: 1/3 Middle and inferior calices:4/3					
Zhu et al., 2017	RCT	147/145	49.9/49.6	86/77	23.7/23.5	55.1/62.8	Prone: 100/100	89/84	Superior calys: 44/46 Middle calys: 92/74 Inferior calys: 26/59	838.3/834.8 mm2	None or mild: 59/64.8 - Moderate or Severe: 40.8/35	N/A	18 F	N/A
Armas-phan et al., 2018	Cohort	138/38	54.6/51	63/18	28.8/30.1	57/56	Prone: 71/29	N/A	N/A	30/32	Yes (n) : 65/15	N/A	24 F	Balloon
Abed et al., 2019	Cohort	35/35	N/A	18/20	N/A	62.9/80	Prone: 100/100	N/A	N/A	N/A		N/A	26 F	Amplatz
Sahan et al., 2020	Retrospective Cohort	72/105	49.2/48.3	34/26	N/A	75/77.1	Prone: 100/100	36.7/45.7	Upper calyx: 28(38.9)/23(21.9)	N/A	None or mild: 30.6/40.9 - Moderate or Severe: 69.4/59.1	N/A	26 F	Ampiatz
Birowo et al., 2020	Cohort	40/80	49.2/54.3	17/47	25.3/25	85/75	Prone: 0/50	40/55	N/A	27.5/34.25	Yes: 50/38.75	N/A	28-30 F	Amplatz
Eslahi et al., 2021	Cohort	35/35	5.68/7.47	25/23	N/A	97.1/94.3	Prone: 100/100		N/A	15.94/19.2	Mild: 57.1/51.4 - Moderate: 34.3/37.1 - Severe: 8.6/11.4	3.5 MHz	15 F	Amplatz

Abbreviations: UG: Ultrasound-guided; FG: Fluoroscopy-guided; RCT: Randomized Clinical Trial; BMI: Body mass index; SFR: Stone-free rate; PCNL: Percutaneous Nephrolithonomy